Showing results (71-80 of 86) with videos related to
Sort By:
Pageof 9
Journal of the American Chemical Society|May 16, 2020
Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase InhibitorsKirsten McAulay, Emily A Hoyt, Morgan Thomas, et al.Bioorganic & Medicinal Chemistry|December 18, 2021
Identification and optimization of a novel series of selective PIP5K inhibitorsDavid M Andrews, Sharon Cartic, Sabina Cosulich, et al.Chemical Communications (Cambridge, England)|December 25, 2013
Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferationMichael J Waring, David M Andrews, Paul F Faulder, et al.Journal of Medicinal Chemistry|November 11, 2022
Mapping Ligand Interactions of Bromodomains BRD4 and ATAD2 with FragLites and PepLites─Halogenated Probes of Druglike and Peptide-like Molecular InteractionsGemma Davison, Mathew P Martin, Shannon Turberville, et al.Journal of Medicinal Chemistry|September 1, 2006
Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugatesGeoff Wells, Christopher R H Martin, Philip W Howard, et al.Journal of Medicinal Chemistry|December 23, 2025
Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current TherapiesHannah L Stewart, Cinzia Bordoni, Claire E Jennings, et al.Journal of Medicinal Chemistry|August 17, 2016
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)Robert H Bradbury, Rowena Callis, Gregory R Carr, et al.Journal of Medicinal Chemistry|August 13, 2013
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)Richard A Ward, Mark J Anderton, Susan Ashton, et al.Molecular Cancer Therapeutics|August 31, 2016
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesGarrett W Rhyasen, Maureen M Hattersley, Yi Yao, et al.Nature Chemical Biology|October 25, 2016
Potent and selective bivalent inhibitors of BET bromodomainsMichael J Waring, Huawei Chen, Alfred A Rabow, et al.Pageof 9